MRKR
Marker Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$23.01M
P/E Ratio
—
EPS
$-0.55
Beta
1.45
52W High
$2.46
52W Low
$0.81
50-Day MA
$1.48
200-Day MA
$1.33
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based immunotherapies and peptide-based vaccines for the treatment of hematologic malignancies and solid tumor indications. The company is headquartered in Houston, Texas.
Fundamentals
| Revenue (TTM) | $3.55M |
| Gross Profit (TTM) | $-7.96M |
| EBITDA | $-11.79M |
| Operating Margin | -338.50% |
| Return on Equity | -77.00% |
| Return on Assets | -43.60% |
| Revenue/Share (TTM) | $0.20 |
| Book Value | $0.83 |
| Price-to-Book | 1.67 |
| Price-to-Sales (TTM) | 6.49 |
| EV/Revenue | 0.721 |
| EV/EBITDA | -0.22 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -51.00% |
| Shares Outstanding | $16.67M |
| Float | $13.81M |
| % Insiders | 5.49% |
| % Institutions | 23.40% |
Historical Volatility
HV 10-Day
52.68%
HV 20-Day
48.71%
HV 30-Day
47.06%
HV 60-Day
65.04%
HV Rank
2.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($7.87 target)
3
BuyMore HEALTHCARE Stocks
Data last updated: 6/13/2026